InvestorsHub Logo
Followers 10
Posts 349
Boards Moderated 0
Alias Born 08/09/2011

Re: None

Thursday, 10/31/2013 11:21:43 PM

Thursday, October 31, 2013 11:21:43 PM

Post# of 425653
LOSING FOCUS upset as we all are at the FDA IMO a diversion away from the real war. That is selling Vascepa scripts. You see back in the 1990's a similar war was fought to get trans fats banned from the US food supply. They were banned in European countries but in the USA the FDA and their corporate buddies resisted and FDA would only mandate they be listed on the food label. The consumer then abruptly stopped buying anything with trans fat.For example the result was Hostess products sales declined rapidly to bankruptcy. You cannot hardly find any food being sold with it on the label in the USA. Amarin needs to play up the more natural way Vascepa accomplishes triglyceride and inflamitory reduction verses the chemical compounds now being used. IMO the same thing will happen even with off label sales. The drastic reduction of side effects by the use of Vascepa is very real as many of it's users have commented on these boards. If that is done IMO the consumer will do the rest and very rapidly so.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News